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WeevaluatedtheeﬀectsofatraditionalChinesemedicine(TCM),namedZeng-xiaoAn-shenZhi-chan2(ZAZ2),onpatientswith
Parkinson’s disease (PD). Among 115 patients with idiopathic PD enrolled (mean age, 64.7 ± 10.2 years old), 110 patients (M =
65, F = 45; mean age, 64.9 ± 10.7 years old) completed the study. Patients took either ZAZ2 (n = 59) or placebo granule (n = 56)
in a blind manner for 13 weeks while maintaining other anti-Parkinson medications unchanged. All participants wore a motion
logger, and we analyzed the power-law temporal autocorrelation of the motion logger records taken on 3 occasions (before, one
week, and 13 weeks after the drug administration). Drug eﬃcacy was evaluated with the conventional Uniﬁed Parkinson Disease
Rating Scale (UPDRS), as well as the power-law exponent α, which corresponds to the level of physical activity of the patients.
ZAZ2 but not placebo granule improved the awake-sleep rhythm, the UPDRS Part II, Part II+III, and Part IV scores, and the α
values. The results indicate that ZAZ2 improved activities of daily living (ADL) of parkinsonism and, thus, is a potentially suitable
drug for long-term use.
1.Introduction
Conventional anti-parkinsonism drugs eﬀectivelyameliorate
the symptoms of patients with Parkinson’s disease (PD)
during the initial several years of onset, but become increas-
ingly less eﬀective and induce motor ﬂuctuations including
wearing-oﬀ,o n - o ﬀ, dopa-induced dyskinesia, and agonist-
induced sleep attack [1–5]. PD patients not infrequently
suﬀer from nonmotor symptoms, such as neuropsychiatric
symptoms, autonomic symptoms, gastrointestinal symp-
toms, sensory symptoms, nonmotor ﬂuctuations (auto-
nomic symptoms, cognitive or psychiatric symptoms, sen-
sory symptoms including pain), fatigue, and sleep distur-
bance[6–8],andthesenonmotorsymptomsmaybeintrinsic
to the disease pathology or may be the result of treatment
with dopaminergic agents. Several studies have established
that the nonmotor symptoms of PD are common, occur
across all stages of PD, and are a key determinant of quality
of life [7].
Herbal remedies have a long history of use (particularly
in East Asian countries) for alleviating various symptoms
and have been increasingly used as alternative medicines
worldwide, including the United States [9]. Traditional
Chinese medicines (TCMs) ameliorate various symptoms,
particularly the ageing-related symptoms [10, 11], and hence
arelikelytobebeneﬁcialforchronicdiseasessuchasPD[12–
14]. Good compliance for long-term use with few side eﬀects
may be another merit of TCM suitable for patients with PD
[12–14].
In order to evaluate the eﬀects of TCM on symptoms
of parkinsonism, we used Zeng-xiao An-shen Zhi-chan 2
(ZAZ2) in this study. In addition, we adopted a recently
developed method analyzing the power-law temporal auto-
correlation of wrist activity measured with a motion logger2 Parkinson’s Disease
[15–17] in order to evaluate the eﬃcacy of ZAZ2 on
parkinsonism.Panetal.showedthatthepower-lawexponent
(α) for higher levels or at the so-called local maxima of
coeﬃcients of the wavelet transform signiﬁcantly and in
correlation with the symptom severity of PD patients [15];
hence analysis of α is likely to be useful for evaluating the
eﬀects of TCM on parkinsonism as a whole. The aim of
the present study was to evaluate the ameliorating eﬀects
of ZAZ2 on impaired motor and nonmotor symptoms of
PD patients using the UPDRS scores, secondary symptoms
scores [18], and also by analyzing the mean activity lev-
els and the power-law temporal exponents of MicroMini-
Motionlogger, Ambulatory Monitoring Inc. (AMI) scores.
2. Methods
2.1. Subjects. Of the 140 PD patients who visited the clinic
at the Department of Neurology of Shuguang Hospital
Aﬃliated to Shanghai University of TCM between July 2008
and April 2010, 115 patients with idiopathic PD (mean
age ± SD, 64.7 ± 10.2 years old, mean duration of illness,
5.5 ± 7.3 years) who fulﬁlled the inclusion criteria, were
invited to participate in the study. The UK Parkinson’s
Disease Society Brain Bank clinical diagnostic criteria were
used [19]. PD was deﬁned by the presence of at least two of
the four cardinal features (bradykinesia, tremor, rigidity, and
postural reﬂex abnormality). Other forms of parkinsonism
based on laboratory tests such as MRI were excluded. All
the patients were at least 40 years of age and were evaluated
in the middle of their levodopa dose cycle at maximal
mobility (on) for the severity of parkinsonism, and signed
informed consent before participation. Next, the patients
were double blindly grouped into the TCM group (n = 59,
64.27 ± 11.8) or the placebo group (n = 56, 63.91 ± 13.9)
(Table 1). Patients were randomly assigned to the ZAZ2
or placebo group and given random numbers by a study
coordinator, who also encoded the drugs with matching
random numbers. Neither the patients nor the researchers
monitoring the outcome knew which patient was receiving
which treatment, until the study was over and the random
code was broken. Anti-parkinsonism drug administration
was not changed throughout the experiment. The study was
approved by The Ethics Committee of Shuguang Hospital
Aﬃliated to Shanghai University of TCM, and performed
under the principles outlined in the Declaration of Helsinki;
all subjects provided informed consent in accordance with
institutionalrequirementspriortoparticipationinthestudy.
2.2. Additional Treatment. Zeng-xiao An-shen Zhi-chan 2
(ZAZ2), the TCM used in this study, is a granule made up of
14 kinds of herbs: Uncaria rhynchophylla 10g, Rehmanniae
radix 10g,C o r n u so ﬃcinalis 8g, Asnaragus cochinchinensic
10g, Paeonia lactiﬂora 10g, Desertliving cistanche 10g,
Puerariae radix 10g, Arisaema consanguineum Schott 10g,
Salviae Miltiorrhizae radix 10g, Acorus tatarinowii 10g,
Curcuma longa Linn 12g,M o r i n d a eo ﬃcinalis radix 10g,
Rhizoma gastrodiae 10g, and Rhizoma chuanxiong 10g.
ZAZ2 is commonly used in “insuﬃciency of Kidney yang”
in China. Placebo granules were made up of 5 kinds of herbs:
Table 1: Patient characteristics.
Placebo (n = 54) ZAZ2 (n = 56)
Age (yr) 63.1 ± 10.2 62.82 ± 10.31
Men/Women 32/22 34/22
Disease duration (yr) 5.81 ± 3.24 5.73 ± 4.81
Hoehn & Yahr stages 2.35 ± 1.33 2.37 ± 1.13
Levodopa/DCI (mg/day) 396.61 ± 159.24 390.59 ± 164.71
Pramipexole (mg/day) 1.03 ± 0.69 1.00 ± 0.79
Selegiline Hydrochloride
(mg/day) 8.97 ± 5.66 9.28 ± 4.95
DCI: decarboxylase inhibitor.
Largehead atractylodes rhizome 10g, Poria cocos (Schw.) wolf
10g,J o b s t e a r ss e e d10g,M a l t10g, and Chinese date 10g.
These5herbshavenoactivityintermsoftraditionalChinese
medicine [13]. Patients were instructed to take one package
(8g) of ZAZ2 or placebo soluble granule three times a day at
least 30min before or after the ingestion of other drugs for
three consecutive months (13 weeks). The shape and color
of ZAZ2 and the placebo soluble granule are very alike and
cannot be distinguished from one another by appearance or
aqueous solution taste. ZAZ2 and the placebo granule were
madebythemanufacturinglaboratoryofShuguangHospital
Aﬃliated to Shanghai University of TCM. The trial was
carried out as a randomized, double-blind, parallel group
study.
2.3. Equipment. All patients wore a small watch-type ac-
tivity monitor equipped with a computer (MicroMini-
Motionlogger, Ambulatory Monitoring, Inc, Ardsley, New
York) on the wrist of their nondominant hand for seven
consecutive days before taking test granule (week 0), one
week (week 1), and 13 weeks (week 13) after taking test
granule. Zero-crossing counts were recorded every one
minute to register and quantify human physical activity [15],
and the data was stored in internal memory. After recording,
data were transmitted to an external computer by software
installed on the device.
2.4. Assessments. Daily proﬁles and mean counts: We plotted
the activity scores for 7 consecutive days to see the daily
proﬁles and biological rhythms of each patient (Figure 1).
The records acquired during awake times and sleep times
were separated with Action-W, Version 2 (Ambulatory
Monitors Inc., Ardsley, NY, USA). The mean counts during
awake times and sleep times were separately calculated for
each record (Table 2 and Figure 2(a)).
UPDRS Scores. The UPDRS of all patients were evaluated
at week 0, week 1, and week 13 by neurologists who were
blinded to the test granule.
Secondary Symptom Score [18]. This score is conventionally
used in China to evaluate the eﬀects of anti-parkinsonism
drugs and consists of 8 parts, including the assessments of
nonﬂuent speech, vertigo, insomnia/nightmares, headache,Parkinson’s Disease 3
Table 2: Results of clinical evaluation between before and after test granule administration.
Placebo (n = 54) ZAZ (n = 56)
Week 0 Week 1 Week 13 Week 0 Week 1 Week 13
UPDRS total score 46.6 ± 16.3 44.7 ± 15.3 45.9 ± 18.1 46.3 ± 17.1 37.1 ± 11.2∗## 40.7 ± 15.1∗#
UPDRS I 2.5 ± 0.7 2.3 ± 1.1 2.4 ± 1.2 2.6 ± 0.8 2.1 ± 0.7∗ 2.3 ± 0.9
UPDRS II 15.7 ± 9.3 14.8 ± 11.2 15.3 ± 11.6 15.9 ± 11.3 12.5 ± 4.6∗# 13.4 ± 9.8∗#
UPDRS III 25.5 ± 12.9 23.8 ± 10.6∗ 24.9 ± 12.7 25.4 ± 10.1 19.3 ± 9.8∗# 21.6 ± 10.4∗
UPDRS IV 3.1 ± 1.1 2.9 ± 1.6 3.0 ± 1.4 3.2 ± 1.4 2.6 ± 0.8∗# 2.7 ± 1.3∗#
Awake time (counts/min) 98.5 ± 14.1 102.6 ± 18.9 100.7 ± 16.9 99.8 ± 17.8 126.7 ± 13.4∗## 118.4 ± 11.8∗##
Sleep time (counts/min) 42.9 ± 17.1 38.8 ± 15.6∗ 40.1 ± 14.8 43.2 ± 11.6 35.6 ± 13.6∗# 32.8 ± 13.6∗#
α (awake time) 0.97 ± 0.21 0.95 ± 0.28 0.96 ± 0.18 0.97 ± 0.24 0.88 ± 0.21∗# 0.86 ± 0.19∗##
α (sleep-time) 1.19 ± 0.28 1.16 ± 0.27 1.15 ± 0.29 1.18 ± 0.26 1.04 ± 0.22∗# 1.02 ± 0.18∗##
Data presented are mean ± SD. ∗P<. 05; ∗∗P<. 01 compared to week 0 (repeated-measure ANOVAs); #P<. 05; ##P<. 01 compared to placebo (Bonferroni
test); UPDRS: Uniﬁed Parkinson’s Disease Rating Scale; α: power-law exponent.
sweating or night sweats, tiredness, sense of cold, and
dysuria. In this study, the secondary symptom scores were
evaluated in week 0, week 1, and week 13 for all participants
by the same neurologists, and it reﬂects the opinion of PD
patients (Table 3).
Power-Law Temporal Analysis α. The methods for power-law
temporal analyses were the same as those described in Pan
et al. [15]. The awake time and sleep time data were used
separately for the power-law temporal analyses. After inte-
grating the time series, the data were wavelet-transformed
using the third derivative of the Gaussian function as the so-
called “mother wavelet.” The wavelet coeﬃcients (W (S)) at
each point along the time series and at diﬀerent timescales
(S) were obtained by convolving the mother wavelet with
the time series. This approach facilitates the probing of
transient increases or decreases in detrended activity records
atdiﬀerenttimescales. The transientincreases (low-high-low
level activity patterns) yielded local maxima of the wavelet
coeﬃcients at their time points, while the decreases (high-
low-high level activity patterns) yielded local minima of the
wavelet coeﬃcients. Next, the squared wavelet coeﬃcients
at the local maxima or minima were averaged for all the
data points, and the power-law exponent (α) was obtained
separately for local maxima and minima as the slope of a
straight line ﬁtted in the double-logarithmic plot of S versus
W( S ) 2 in the range of S corresponding to 8 to 35min. The
power-law exponent of maxima has been successfully used
for the assessment for PD in previous studies [15, 20]. In this
study, we analyzed the local maxima separately for the awake
time and sleep time of each record (Table 2 and Figure 2(b)).
For the safety assessments, each patient underwent a
physical examination by a physician and laboratory tests for
blood counts and biochemistry, and urinalysis at each visit.
2.5. Statistical Analysis. Repeated-measure ANOVAs were
conducted to test the diﬀerences among week 0, week 1, and
week 13 in the ZAZ2 and placebo groups. When a signiﬁcant
diﬀerence was detected, a post-hoc test (Bonferroni test) was
conducted between the ZAZ2 and placebo groups compared
for the UPDRS total score, UPDRS Part I, Part II, Part III,
Part II + Part III, and Part IV, mean values, and the power-
law temporal α in awake time and sleep time. A signiﬁcant
diﬀerencewasdeﬁnedasP<. 05.SPSSwindowsVersion17.0
was used for statistical analyses. All data are expressed as the
mean ± standard deviation.
3. Results
Five patients dropped out of the study; one patient in the
ZAZ2 group was unable to tolerate the bitter taste of ZAZ2,
while two in the ZAZ2 group and two in the placebo group
dropped out due to a conﬂict with other TCM prescribed
for concomitant diseases. Neither physical examination nor
laboratory tests revealed any adverse changes after additional
treatment in either group.
The post-hoc test revealed no signiﬁcant diﬀerences in
baseline (week 0) UPDRS scores, Hoehn & Yahr stages, mean
counts, and power-law temporal exponent α values, or in the
dosage of L-dopa/DCI, Dopamine agonist or monoamine
oxidase B, between the ZAZ2 and placebo groups (Tables 1
and 2).
Daily proﬁles of AMI counts clearly demonstrated
improvement of the biological rhythm after the additional
treatment in the ZAZ2 group (Figure 1(a)) but not in the
placebo group (Figure 1(b)). Patients in the ZAZ2 group
showed a more frequent switch from high activity to low
activity in awake time and lower activity during sleep time
after ZAZ2 than before ZAZ2 (Figures 1(a) and 2(a), Table 2,
P<. 05, Bonferroni test). Such changes were not observed
after placebo granule intake (Figures 1(b) and 2(a), Table 2).
When the eﬀects of ZAZ2 were evaluated with UPDRS
scores, signiﬁcant and persistent improvements were found
in the part II, parts II + III, and part IV scores (Table 2).
Although some parts of UPDRS improved in week 1 in both
the ZAZ2 and placebo groups, the improvement did not
persist until week 13 (repeated-measure ANOVAs Table 2).
There were signiﬁcant diﬀerences in UPDRS Part II, Part II
+ Part III, and Part IV scores at week 13 between the ZAZ2
group and placebo group (P<. 05, Bonferroni test; Table 2).
The local power-law exponent α, given by a slope of the
log S versus log W (S)2 relationship, characterizes the nature4 Parkinson’s Disease
Table 3: Eﬀects on secondary symptoms of PD.
Group Time Nonﬂuent
speech Vertigo Insomnia/
nightmare Headache Sweating or
night sweats Tiredness Sense of cold Dysuria
Placebo
0 weeks 1.12±0.59 1.31±0.97 2.67±0.87 1.03±0.75 2.13±1.32 1.70±0.97 1.78±0.39 2.29±1.02
1 weeks 0.69±0.32∗ 1.12±0.69 2.40±0.69∗ 0.96±0.36∗ 1.87±0.58 1.35±0.69∗ 1.39±0.81 1.69±0.92∗
13 weeks 1.02±0.36 1.28±0.53 2.45±0.38 0.99±0.65 2.18±0.56 1.58±0.66 1.64±0.58 2.18±1.30
ZAZ2
0 weeks 1.08±0.74 1.33±0.83 2.77±0.98 0.92±0.56 2.11±0.68 1.66±0.57 1.90±0.67 2.23±0.69
1 weeks 0.56±0.28∗ 0.84±0.26∗# 2.03±0.78∗ 0.64±0.28∗## 1.38±0.69∗# 1.21±0.46∗ 1.48±0.57∗ 1.43±0.31∗#
13 weeks 0.65±0.33∗## 0.95±0.37∗# 1.73±0.38∗# 0.63±0.19∗# 1.48±0.28∗## 1.27±0.51∗# 1.58±0.61 1.46±0.36∗##
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Figure 1: Daily proﬁles of AMI counts demonstrated the biological rhythm after granule ingestion in the ZAZ2 group (a) and in the placebo
group (b). Each dash in the recordings represents midnight.
of “switching” patterns between high and low values in a
statistical sense. The average wavelet coeﬃcients exhibited
linear relationships in the range of scales from 8min to
35min both for the ZAZ2 and placebo groups (Figure 2(b)).
The local power-law exponent α values during both awake
time and sleep time were signiﬁcantly decreased both 1 week
and 13 weeks after taking ZAZ2, but not after taking placebo
granule (Table 2 and Figure 2(c), P<. 01; Bonferroni test).
As the exploratory outcome of this study, most of the
secondary symptoms were improved by the ZAZ2 treatment,
whereas only a few symptoms in the placebo group were
transiently improved in week 1 (Table 3).
4. Discussion
Inthisstudy,wedemonstratethatZAZ2,aTCM,ameliorates
the disability of PD patients using the analysis of power-law
temporal autocorrelation of the AMI records together with
conventional UPDRS. Because a recent study indicated that
improvement of the scores in UPDRS Part II reﬂect the long-
term outcome of the patients [21], improvements of scores
in UPDRS Part II, II + III, and IV likely reﬂect the beneﬁcial
eﬀects of ZAZ2 on the patients’ overall ADL as an endpoint
of the treatment. ZAZ2 induced no signiﬁcant adverse eﬀects
and was tolerable by more than 98% of the participants.
We previously demonstrated that the change in the
local power-law exponent α is a quantitative predictor for
evaluating the akinesia changes in PD [15, 20]. Because
the α-values indicate persistency, lower α-values correspond
to more frequent switching of behavior or higher physical
activity [15, 20]. Therefore, the signiﬁcant reduction in the
α-values after ZAZ2 likely represents the improvement of
motor function of the patients as a whole, which is in
accordance with the improvement of scores of UPDRS Part
II and Part II + Part III.
The eﬀects of ZAZ2 are also demonstrated by the
improvement in the scores for the secondary symptoms
































































































Figure 2: Before and after administration of granules of ZAZ2 and placebo for mean counts of physical activity (a), average wavelet
coeﬃcients, as a function of the wavelet scale for awake time and sleep-time, the slopes are power-law exponents, α (b), and comparisons of
the mean α (c).
exploratory outcomes of this study. Indeed, activity during
sleep time was markedly decreased and the local power-law
exponent α was signiﬁcantly decreased during sleep time as
well as during awake time (Figures 2(a) and 2(c)). Because
sleep disturbance, which is frequent among patients with
PD, is thought to be due to disruption of the nighttime
eﬀects of levodopa [22], improvement of wake-sleep rhythm
is likely a reﬂection of an improvement in parkinsonism.
ZAZ2 may have beneﬁcial eﬀects on ADL by ameliorating
the symptoms resulting from parkinsonism without exacer-
bating the L-dopa-induced adverse eﬀects, as demonstrated
in the improvement in scores of UPDRS Part IV.
TCM ameliorates various symptoms, particularly the
ageing-related symptoms that are called shen xu (kidney
deﬁciency) in Chinese [10, 11]. Shen (the kidney) denotes
a functional visceral system (zang) that plays a central role
in the regulation of growth, maturation, and ageing, and
is subdivided into shen yang (kidney yang) and shen yin
(kidney yin). Kidney yang can be described as the driving
forcesofallmetabolicprocessesthatimprovethemovements
of the body. The production of kidney yin is considered
to be eﬀective at increasing nutrition to the muscles and
improving the smoothness of the movements of the body
by constituting the structive potential for the production of
kidney yang. Based on this concept, TCM aims to potentiate
a diminishing vitality of this transformative cycle caused by a
decline of the essence (jing), which is stored in the kidneys
and underpins the functions of both kidney yin and yang
[23, 24].
Among the 14 components of ZAZ2, Morindae oﬃcinalis
radix and Desertliving Cistanche might strengthen the “kid-
ney yang” while Asnaragus cochinchinensic, Cornus oﬃcinalis,
and Rehmanniae radix might increase the “kidney yin.” The
other components ameliorate secondary symptoms such as6 Parkinson’s Disease
headache, vertigo, and tinnitus (Uncaria rhynchophylla and
Rhizoma gastrodiae), enhance the strength of the “kidney”
(Paeonia lactiﬂora, Puerariae radix, Salviae Miltiorrhizae
radix, Curcuma longa Linn, and Rhizoma chuanxiong), or
increase blood circulation in the brain (Arisaema con-
sanguineum Schott and Acorus tatarinowii). In addition,
the inhibitory eﬀects of TCM on ﬁbril formation and
inhibited Aβ aggregation (Uncaria rhynchophylla) [25], and
on apoptosis and the neurobehavioral impairment of 1-
methyl-4-phenylpyridinium ion (MPP+)-induced PD model
mice (desertliving Cistanche) [26, 27] and rats (Uncaria
rhynchophylla, Cornus oﬃcinalis, Rehmanniae radix, and
Paeonia lactiﬂora)[ 28] have been reported. Whether the
herbs in ZAZ2 contain L-dopa or anticholinergic agents has
not been demonstrated. Therefore, ZAZ2 may be potentially
eﬀective in the regulation of motor and various nonmotor
symptoms of patients with PD without inducing the adverse
eﬀects of conventional anti-parkinsonism drugs. ZAZ2 is
tolerable for long-term administration, and hence is likely a
suitablechoiceasanadditional drugforlong-termcontrolof
the symptoms of PD.
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